10 January 2024 
EMA/13649/2024  
Human Medicines Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Brintellix 
vortioxetine 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package 
See Annex A 
size(s): 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  H. Lundbeck A/S 
Ottiliavej 9 
DK 2500 Valby 
DENMARK 
Procedure  
Procedure number: 
EMEA/H/C/002717/IB/0040 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan EMEA-C-000455-PIP02-10-M09. All studies in the agreed paediatric investigation plan EMEA-C-
000455-PIP02-10-M09 were conducted after the entry into force of that Regulation, 
-the Summary of Product Characteristics has been updated in section 5.1 to reflect the results of 
studies conducted in compliance with this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance 
with the agreed completed paediatric investigation plan EMEA-C-000455-PIP02-10-M09 is included in 
the technical dossier. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
 
 
 
 
 
 
 
 
 
 
EMA/13649/2024 
Page 2/2
 
 
 
  
 
